A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer



Summary

This phase Ib/II trial investigated the efficacy and safety of atezolizumab (an immunotherapy drug) combined with either cobimetinib (a MEK inhibitor) or idasanutlin (an MDM2 inhibitor) in patients with metastatic estrogen receptor-positive (ER+) breast cancer. The goal was to determine if these combinations could overcome endocrine resistance and improve outcomes. The study involved two arms, each evaluating atezolizumab plus one of the targeted therapies. Preliminary results focused on assessing response rates, progression-free survival, and safety profiles to determine the potential of these combinations in this challenging patient population.

This post is part of “Immunology News”, Follow for more…!!!

Click on Source link for more details